Language selection

Government of Canada / Gouvernement du Canada

Search

Literature review on the immunogenicity of herpes zoster vaccines .: HP40-243/2018E-PDF

"Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines"--Executive summary, p. 3.

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.865656&sl=0

Publication information
Department/Agency
  • Public Health Agency of Canada.
TitleLiterature review on the immunogenicity of herpes zoster vaccines .
Publication typeMonograph
Language[English]
Other language editions[French]
FormatDigital text
Electronic document
Note(s)
  • Issued also in French under title: Revue de la littérature sur l'immunogénicité des vaccins contre le zona.
  • "Publication date: January 2019."
  • "An Advisory Committee Review (ACR), National Advisory Committee on Immunization (NACI)."
  • Cover title.
  • Includes bibliographical references.
Publishing information
  • [Ottawa] : Public Health Agency of Canada, 2019.
Description46 p.
ISBN9780660288628
Catalogue number
  • HP40-243/2018E-PDF
Departmental catalogue numberPub. : 180582
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details

Report a problem or mistake on this page
Date modified: